J 2021

COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study

CHATZIKONSTANTINOU, T., A. KAPETANAKIS, L. SCARFO, G. KARAKATSOULIS, D. ALLSUP et. al.

Základní údaje

Originální název

COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study

Autoři

CHATZIKONSTANTINOU, T., A. KAPETANAKIS, L. SCARFO, G. KARAKATSOULIS, D. ALLSUP, A. A. CABRERO, M. ANDRES, D. ANTIC, M. BAILE, P. BALIAKAS, D. BRON, A. CAPASSO, S. CHATZILEONTIADOU, R. CORDOBA, J.G. CORREA, C. CUELLAR-GARCIA, L. DE PAOLI, M. R. DE PAOLIS, G. DEL POETA, C. DEMOSTHENOUS, M. DIMOU, D. DONALDSON, Michael DOUBEK (203 Česká republika, domácí), M. EFSTATHOPOULOU, B. EICHHORST, S. EL-ASHWAH, A. ENRICO, B. ESPINET, L. FARINA, A. FERRARI, M. FOGLIETTA, H. FREDERIKSEN, M. FURSTENAU, J. A. GARCIA-MARCO, R. GARCIA-SERRA, M. GENTILE, E. GIMENO, A. GLENTHOJ, M. G. DA SILVA, O. GUTWEIN, Y. K. HAKOBYAN, Y. HERISHANU, J. A. HERNANDEZ-RIVAS, T. HEROLD, I. INNOCENTI, G. ITCHAKI, O. JAKSIC, A. JANSSENS, O. B. KALASHNIKOVA, E. KALICINSKA, L. K. KARLSSON, A. P. KATER, S. KERSTING, J. LABRADOR, D. LAD, L. LAURENTI, M. D. LEVIN, E. LISTA, A. LOPEZ-GARCIA, L. MALERBA, R. MARASCA, M. MARCHETTI, J. MARQUET, M. MATTSSON, F. R. MAURO, I. MILOSEVIC, F. MIRAS, M. MORAWSKA, M. MOTTA, T. MUNIR, R. MURRU, C. U. NIEMANN, R. N. RODRIGUES, J. OLIVIERI, L. ORSUCCI, M. PAPAIOANNOU, M. A. PAVLOVSKY, I. PISKUNOVA, V. M. POPOV, F. M. QUAGLIA, G. QUARESMINI, K. QVIST, G. REDA, G. M. RIGOLIN, R. RUCHLEMER, G. SAGHUMYAN, A. SHRESTHA, M. SIMKOVIC, M. SPACEK, P. SPORTOLETTI, O. STANCA, N. STAVROYIANNI, T. TADMOR, D. TE RAA, S. H. TONINO, L. TRENTIN, E. VAN DER SPEK, M. VAN GELDER, R. VAN KAMPEN, M. VARETTONI, A. VISENTIN, C. VITALE, E. WASIK-SZCZEPANEK, T. WROBEL, L. Y. SAN SEGUNDO, M. YASSIN, M. COSCIA, A. RAMBALDI, E. MONTSERRAT, R. FOA, A. CUNEO, K. STAMATOPOULOS a P. GHIA

Vydání

Leukemia, London, Nature Publishing Group, 2021, 0887-6924

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 12.883

Kód RIV

RIV/00216224:14110/21:00123869

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1038/s41375-021-01450-8

UT WoS

000713599200001

Klíčová slova anglicky

COVID-19; severity; mortality; CLL

Štítky

14110212, 14110323, rivok

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 20. 1. 2022 14:42, Mgr. Tereza Miškechová

Anotace

V originále

Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to Coronavirus disease 2019 (COVID-19) due to age, disease, and treatment-related immunosuppression. We aimed to assess risk factors of outcome and elucidate the impact of CLL-directed treatments on the course of COVID-19. We conducted a retrospective, international study, collectively including 941 patients with CLL and confirmed COVID-19. Data from the beginning of the pandemic until March 16, 2021, were collected from 91 centers. The risk factors of case fatality rate (CFR), disease severity, and overall survival (OS) were investigated. OS analysis was restricted to patients with severe COVID-19 (definition: hospitalization with need of oxygen or admission into an intensive care unit). CFR in patients with severe COVID-19 was 38.4%. OS was inferior for patients in all treatment categories compared to untreated (p < 0.001). Untreated patients had a lower risk of death (HR = 0.54, 95% CI:0.41-0.72). The risk of death was higher for older patients and those suffering from cardiac failure (HR = 1.03, 95% CI:1.02-1.04; HR = 1.79, 95% CI:1.04-3.07, respectively). Age, CLL-directed treatment, and cardiac failure were significant risk factors of OS. Untreated patients had a better chance of survival than those on treatment or recently treated.
Zobrazeno: 4. 11. 2024 02:17